» Articles » PMID: 35575750

A Systematic Review and Meta-Analysis of the Association Between Polycystic Ovary Syndrome and Coronary Artery Calcification

Overview
Date 2022 May 16
PMID 35575750
Authors
Affiliations
Soon will be listed here.
Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine pathology affecting women of reproductive age characterized by chronic anovulation, hyperandrogenism, and polycystic ovaries. Coronary artery calcification (CAC) is a marker of subclinical atherosclerosis and prognostic of cardiovascular disease (CVD) risk. Some studies have shown that women with PCOS have a greater risk of CAC; however, a few others report contrary findings. The objective of this study is to examine and quantify the association between PCOS and CAC. We searched EMBASE, Google Scholar, PubMed, and Web of Science from inception to November 2021 to identify studies that provided information on PCOS and CAC. We used a random-effects model to aggregate the odds ratios (ORs) for CAC (score >0) among women with PCOS compared with controls adjusted for sociodemographic characteristics and CVD risk factors. From the 36 articles reviewed, 3 prospective cohort and 4 cross-sectional studies met the inclusion criteria with a total of 2341 participants. Six studies used CAC > 0 as an outcome and were included in the pooled analysis. Using the Hartung-Knapp-Sidik-Jonkman method, the pooled adjusted ORs for the associations between PCOS and the presence of CAC were 2.48 (95% confidence interval: 2.11-2.84) with no significant heterogeneity ( = 0.10%,  = 0.97) for the cohort studies and 1.88 (0.71-3.06) with no significant heterogeneity ( = 13.95%,  = 0.87) for the cross-sectional studies. In pooled analyses, women with PCOS had approximately twofold greater odds of having CAC compared with women without PCOS. However, additional prospective studies will be needed to further understand the relationship between PCOS and CAC.

Citing Articles

The Current and Emerging Role of Statins in the Treatment of PCOS: The Evidence to Date.

Kolnikaj T, Herman R, Janez A, Jensterle M Medicina (Kaunas). 2024; 60(2).

PMID: 38399531 PMC: 10890374. DOI: 10.3390/medicina60020244.


Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women-What Is the Evidence?.

Linden Hirschberg A J Clin Endocrinol Metab. 2023; 109(5):1202-1213.

PMID: 37886900 PMC: 11031217. DOI: 10.1210/clinem/dgad590.


Assisted reproductive technology: what are the cardiovascular risks for women?.

Guan C, Rodriguez C, Elder-Odame P, Minhas A, Zahid S, Baker V Expert Rev Cardiovasc Ther. 2023; 21(10):663-673.

PMID: 37779500 PMC: 10615881. DOI: 10.1080/14779072.2023.2266355.


Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women.

Rajendran A, Minhas A, Kazzi B, Varma B, Choi E, Thakkar A Atherosclerosis. 2023; 384:117269.

PMID: 37752027 PMC: 10841060. DOI: 10.1016/j.atherosclerosis.2023.117269.


A Woman's Heart: Improving Uptake and Awareness of Cardiovascular Screening for Middle-Aged Populations.

Kazzi B, Shankar B, Elder-Odame P, Tokgozoglu L, Sierra-Galan L, Michos E Int J Womens Health. 2023; 15:1171-1183.

PMID: 37520181 PMC: 10377626. DOI: 10.2147/IJWH.S328441.

References
1.
Oliver-Williams C, Vassard D, Pinborg A, Schmidt L . Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study. Eur J Prev Cardiol. 2020; 28(12):e39-e41. DOI: 10.1177/2047487320939674. View

2.
Gao L, Zhao F, Li S . Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials. Exp Clin Endocrinol Diabetes. 2012; 120(6):367-75. DOI: 10.1055/s-0032-1304619. View

3.
Snyder M, Shields K, Korytkowski M, Sutton-Tyrrell K, Talbott E . Complement protein C3 and coronary artery calcium in middle-aged women with polycystic ovary syndrome and controls. Gynecol Endocrinol. 2014; 30(7):511-5. PMC: 4065194. DOI: 10.3109/09513590.2014.895985. View

4.
Michos E, Blaha M, Blumenthal R . Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. Mayo Clin Proc. 2017; 92(12):1831-1841. DOI: 10.1016/j.mayocp.2017.10.001. View

5.
Niafar M, Pourafkari L, Porhomayon J, Nader N . A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2015; 293(3):509-15. DOI: 10.1007/s00404-015-3976-7. View